Skip to main content
Download PDF
- Main
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077
- Landovitz, Raphael J;
- Zangeneh, Sahar Z;
- Chau, Gordon;
- Grinsztejn, Beatriz;
- Eron, Joseph J;
- Dawood, Halima;
- Magnus, Manya;
- Liu, Albert Y;
- Panchia, Ravindre;
- Hosseinipour, Mina C;
- Kofron, Ryan;
- Margolis, David A;
- Rinehart, Alex;
- Adeyeye, Adeola;
- Burns, David;
- McCauley, Marybeth;
- Cohen, Myron S;
- Currier, Judith S
- et al.
Published Web Location
https://doi.org/10.1093/cid/ciz439Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%